Efficacy of Alirocumab in the arteriosclerotic biomarker changes after percutaneous coronary angioplasty (PCI).
Not Applicable
Recruiting
- Conditions
- coronary heart disease
- Registration Number
- JPRN-UMIN000032843
- Lead Sponsor
- Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
-HMG-CoA reductase inhibitor is not used at the time of introduction -At the time of introduction of research drugs, patients with LDL-C less than 100 mg / dL -Contraindicated patients with HMG-CoA reductase inhibitors -Hypersensitivity to the study drug
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method assessment of myocardial remodering suppression effect after 32 to 40 weeks.
- Secondary Outcome Measures
Name Time Method assessment of coronary plaque imaging, serum biomarkers and coronary microcirculation after 32 to 40 weeks.